Clinical Trials Logo

Clinical Trial Summary

The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function.


Clinical Trial Description

Background: Hemodialysis patients have a mortality rate 50 times higher than in the general population, and the cause remains cardiovascular in more than half of the cases. A deleterious morphological and functional cardiac remodelling is well established in these patients, the causes of which are both the presence of factors specific to renal disease (hemodynamic and non-hemodynamic) and co-morbidities (diabetes, hypertension, etc. .) but also to the hemodialysis (HD) procedure itself, due to the sudden hemodynamic changes it imposes, leading to repeated episodes of intradialytic hypotension (HID) and myocardial stunning. The latter are now documented as direct contributors to the increased mortality observed in HD patients compared to the general population. The introduction of intradialytic physical exercise in the therapeutic program of HD patient is now recommended and practised routinely in many countries, in Scandinavia in particular. Several meta-analyses have clearly established its safety. The beneficial role of chronic intradialytic exercise in improving dialysis efficiency, mental health and quality of life, as well as the inflammatory status of HD patients is also clearly demonstrated. Chronic intradialytic exercise is also associated with improvements in overall fitness level, a parameter closely linked to cardiovascular mortality. Applied acutely during dialysis, it could play a cardioprotective role (e.g; limiting myocardial stunning), allowing haemodynamic and cardiac functional stabilization during HD. However, to our knowledge, no study to date has investigated the long-term effects of intradialytic exercise on remodelling and overall and regional heart function. Aims: The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function. The secondary objectives are to evaluate the effect of acute intradialytic exercise on myocardial stunning as well as the effect of chronic physical exercise on macro and microcirculatory vascular function, inflammation, physical fitness and health-related quality of life. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04697459
Study type Interventional
Source University of Avignon
Contact
Status Completed
Phase N/A
Start date December 13, 2020
Completion date September 30, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3